Century Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Brent Pfeiffenberger

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	2.9yrs

Recent management updates

Recent updates

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Mar 06

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Feb 01

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Oct 23

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Aug 25

CEO

Brent Pfeiffenberger

less than a year

Tenure

Mr. Brent Pfeiffenberger, Pharm D., MBA, has been Chief Executive Officer and Director of Century Therapeutics, Inc. since December 04, 2023. He served as Chief Operating Officer at Neogene Therapeutics, I...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Adrienne Farid	COO & Head of Early Development	3yrs	US$1.55m	0.10% $ 242.1k
Brent Pfeiffenberger	CEO & Director	less than a year	no data	no data
Douglas Carr	Interim Principal Financial Officer	less than a year	no data	0.28% $ 667.9k
Gregory Russotti	Chief Technology & Manufacturing Officer	less than a year	no data	0.11% $ 267.2k
Kenneth Dow	Senior VP of General Counsel	no data	no data	no data
Shane Williams	Chief People Officer	no data	no data	no data
Hyam Levitsky	President of Research & Development	less than a year	US$502.13k	0.65% $ 1.5m
Michael Naso	Senior VP of Cell Engineering	less than a year	no data	no data
Nick Trede	Senior VP & Head of Clinical Development	1.3yrs	no data	no data

0.9yrs

Average Tenure

61yo

Average Age

Experienced Management: IPSC's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Brent Pfeiffenberger	CEO & Director	less than a year	no data	no data
Cynthia Butitta	Independent Director	3.2yrs	US$164.75k	0.12% $ 284.9k
Joseph Jimenez	Independent Chairman of the Board	5.3yrs	US$187.75k	0.60% $ 1.4m
Timothy Walbert	Independent Director	1.6yrs	US$273.89k	0% $ 0
Alessandro Riva	Independent Director	2.9yrs	US$152.25k	0% $ 0
Daphne Quimi	Independent Director	1.6yrs	US$275.51k	0% $ 0
Carlo Rizzuto	Independent Director	3.2yrs	US$158.75k	0% $ 0
Kimberly Blackwell	Independent Director	2.9yrs	US$156.25k	0% $ 0

2.9yrs

Average Tenure

59.5yo

Average Age

Experienced Board: IPSC's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Century Therapeutics Management

Management criteria checks 0/4

Key information

Recent management updates

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

Chief Scientific Officer recently sold US$55k worth of stock

Recent updates

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors

Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million.

Consensus revenue estimates decrease by 86%, EPS upgraded

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

New minor risk - Share price stability

Consensus revenue estimates fall by 32%

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

New major risk - Financial position

New minor risk - Market cap size

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00

Consensus revenue estimates decrease by 48%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Price target decreased by 9.2% to US$17.89

Price target decreased by 8.6% to US$18.00

Chief Scientific Officer recently sold US$55k worth of stock

Chief Scientific Officer exercised options and sold US$351k worth of stock

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Elipse-1 Trial Evaluating Cnty-101 in Relapsed or Refractory Cd19 Positive B-Cell Lymphomas

Price target decreased to US$20.30

Consensus revenue estimates increase by 26%

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Preclinical Data At the SITC 37Th Annual Meeting and Provides Pipeline Updates

Price target decreased to US$22.44

Casdin Capital Engages in Discussions with Century Therapeutics

Century Therapeutics, Inc. Announces Board Changes

Century Therapeutics, Inc. Receives Study May Proceed Notification from FDA for CNTY-101

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Consensus revenue estimates fall by 20%

Century Therapeutics, Inc.(NasdaqGS:IPSC) dropped from Russell 2000 Growth Index

Consensus revenue estimates increase by 2,133%

High number of new and inexperienced directors

Century Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Data At the 63Rd American Society of Hematology Annual Meeting and Provides Pipeline Updates

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age